Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with craniotomy for supratentorial tumors under general anesthesia~* American Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients~* Elective surgery~* Patients with Glasgow Coma Scale (GCS) 15/15~Exclusion Criteria:~* Patients with a history of allergy or hypersensitivity to tramadol.~* History of epilepsy or convulsions due to any reason.~* Chronic usage of analgesic drugs.~* Patients using monoamine oxidase inhibitors.~* Patients with clinical signs of raised ICP.~* Obesity (women with a body mass index \>35 kg/m2 or men with a body mass index \>42 kg/m2)~* Language barrier.~* Patients taking B-blockers or Ca channel blockers.~* Patients above 65 years of age ( Physiology difference)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tramadol (Type: EXPERIMENTAL): Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
- Placebo (Type: PLACEBO_COMPARATOR): 0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure

Based on this trial design, predict the completion outcome and termination type (if applicable).